152193-00-5

Usage

Uses

Used in Pharmaceutical Industry:
(2-AMINOETHYL)-BENZYLCARBAMICACIDTERT-BUTYLESTER is used as a chemical intermediate for the synthesis of various drug compounds, contributing to the development of new medications.
Used in Antiviral and Antibacterial Applications:
(2-AMINOETHYL)-BENZYLCARBAMICACIDTERT-BUTYLESTER is used as a potential antiviral and antibacterial agent, making it a valuable component in the development of new medications to combat viral and bacterial infections.
Used in Organic Synthesis:
(2-AMINOETHYL)-BENZYLCARBAMICACIDTERT-BUTYLESTER is used as a protecting group for sensitive functional groups in organic synthesis, thanks to the presence of the tert-butyl ester group in its structure. This feature enhances the compound's utility in research and industry.

InChI:InChI=1/C14H22N2O2/c1-14(2,3)18-13(17)16(10-9-15)11-12-7-5-4-6-8-12/h4-8H,9-11,15H2,1-3H3

Upstream product

• 4152-09-4 N-benzylethylenediamine 
• 1018908-83-2 tert-butyl (2-azidoethyl)(benzyl)carbamate 
• 104-63-2 N-Benzylethanolamine 
• 121496-39-7 N-(tert-butoxycarbonyl)-N-benzylethanolamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 100-46-9 benzylamine 
• 76315-01-0 N-benzyl-N-(tert-butoxycarbonyl)glycine 
• 3010-05-7 benzylaminoacetonitrile 
• 194207-16-4 Benzyl-carbamoylmethyl-carbamic acid tert-butyl ester 
• 194207-87-9 Benzyl-cyanomethyl-carbamic acid tert-butyl ester 
• 152192-99-9 N₁-tert-butoxycarbonyl-N₁-benzyl-N₂-phthalyl-1,2-ethanediamine 

Downstream Products

• 194208-14-5 [2-(Benzyl-tert-butoxycarbonyl-amino)-ethyl]-carbamic acid 4-nitro-phenyl ester 
• 263758-27-6 C₂₂H₂₇N₃O₈S 
• 263758-31-2 C₂₈H₄₀N₂O₆ 

Relevant academic research and scientific papers

Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping

Selective inhibition of neuronal nitric oxide synthase (nNOS) has been shown to prevent brain injury and is important for the treatment of various neurodegenerative disorders. This study shows that not only greater inhibitory potency and isozyme selectivity but more druglike properties can be achieved by fragment hopping. On the basis of the structure of lead molecule 6, fragment hopping effectively extracted the minimal pharmacophoric elements in the active site of nNOS for ligand hydrophobic and steric interactions and generated appropriate lipophilic fragments for lead optimization. More potent and selective inhibitors with better druglike properties were obtained within the design of 20 derivatives (compounds 7-26). Our structure - based inhibitor design for nNOS and SAR analysis reveal the robustness and efficiency of fragment hopping in lead discovery and structural optimization, which implicates a broad application of this approach to many other therapeutic targets for which known druglike small-molecule modulators are still limited.

POTENT AND HIGHLY SELECTIVE HETEROAROMATIC INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE

Peptidomimetic compounds as can inhibit neuronal nitric oxide synthase (nNOS) for potential treatment in neurodegenerative diseases, such as but not limited to stroke, Alzheimer's disease, Parkinson's disease, Huntington's disease.

Efficient and scalable method for the selective alkylation and acylation of secondary amines in the presence of primary amines

Selective substitution of secondary amines in the presence of primary amines is performed by using the reaction solvent, methyl isobutylketone (MIBK), as a temporary protecting group for the primary amine. After acylation or alkylation of the secondary amine, the resulting imine intermediate is smoothly hydrolysed, leading to the free primary amine in high yield and purity. This procedure represents a cheap and scalable alternative to multistep methods requiring several protections and deprotections.

HETEROAROMATIC SELECTIVE INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE

Compounds inhibiting neuronal nitric oxide synthase (nNOS) for potential treatment in neurodegenerative diseases, such as stroke, Alzheimer's disease, Parkinson's disease, Huntington's disease, such compounds of a formula.

Approaches to the synthesis of ureapeptoid peptidomimetics

Ureapeptoid peptidomimetics can be composed from Boc-protected N-substituted ethylenediamines. The best approach is to synthesize these from chloroacetonitrile followed by conversion to the corresponding crystalline p-nitrophenyl carbamates in order to prepare the ureapeptoids.